Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
3019341 | Revista Española de Cardiología Suplementos | 2015 | 4 Pages |
Abstract
The joint guidelines of the European Society of Cardiology and the European Atherosclerosis Society on the management of dyslipidemia include a number of interesting clinical features: risk stratification provides the basis for selecting the type and intensity of lipid-lowering treatment; the principal therapeutic target is the low-density lipoprotein cholesterol level; the precise treatment target for this parameter depends on the level of risk (<70Â mg/dl for very-high-risk patients and <100Â mg/dl for high-risk patients); potent statins, given at a high dose, are the drugs of choice for achieving these goals; and particular recommendations must be followed for a number of common clinical scenarios: e.g. the elderly, women, patients with chronic kidney disease and secondary prevention.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Eduardo AlegrÃa-Ezquerra, Eduardo AlegrÃa-Barrero, Ana AlegrÃa-Barrero,